메뉴 건너뛰기




Volumn 40, Issue 7, 2017, Pages 832-838

Toward defining the threshold between low and high glucose variability in diabetes

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; INSULINOTROPIC AGENT; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

EID: 85016207511     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-1769     Document Type: Article
Times cited : (274)

References (40)
  • 1
    • 0027370108 scopus 로고
    • The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetesmellitus
    • TheDiabetes Control and Complications Trial Research Group
    • TheDiabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetesmellitus. N Engl JMed 1993;329:977-986
    • (1993) N Engl JMed , vol.329 , pp. 977-986
  • 2
    • 84964776844 scopus 로고    scopus 로고
    • Intensive diabetic treatment and cardiovascular outcomes in type 1 diabetes: The DCCT/EDIC study 30-year follow-up
    • Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group
    • Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetic treatment and cardiovascular outcomes in type 1 diabetes: The DCCT/EDIC study 30-year follow-up. Diabetes Care 2016;39:686-693
    • (2016) Diabetes Care , vol.39 , pp. 686-693
  • 4
    • 84930532577 scopus 로고    scopus 로고
    • Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes
    • VADT Investigators
    • Hayward RA, Reaven PD, Wiitala WL, et al.; VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;372:2197-2206
    • (2015) N Engl J Med , vol.372 , pp. 2197-2206
    • Hayward, R.A.1    Reaven, P.D.2    Wiitala, W.L.3
  • 5
    • 84857238041 scopus 로고    scopus 로고
    • The glycemic triumvirate and diabetic complications: Is the whole greater than the sum of its component parts?
    • Monnier L, Colette C, Owens D. The glycemic triumvirate and diabetic complications: is the whole greater than the sum of its component parts? Diabetes Res Clin Pract 2012;95:303-311
    • (2012) Diabetes Res Clin Pract , vol.95 , pp. 303-311
    • Monnier, L.1    Colette, C.2    Owens, D.3
  • 6
    • 84919999219 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • Inzucchi SE, Bergenstal RM, Buse JB, et al.Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study ofDiabetes. Diabetes Care 2015;38:140-149
    • (2015) Diabetes Care , vol.38 , pp. 140-149
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 7
    • 33645745733 scopus 로고    scopus 로고
    • Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes
    • Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-1687
    • (2006) JAMA , vol.295 , pp. 1681-1687
    • Monnier, L.1    Mas, E.2    Ginet, C.3
  • 8
    • 84962360946 scopus 로고    scopus 로고
    • Glycemic variability and diabetes complications: Does it matter? of course it does
    • Hirsch IB. Glycemic variability and diabetes complications: Does it matter? Of course it does! Diabetes Care 2015;38:1610-1614
    • (2015) Diabetes Care , vol.38 , pp. 1610-1614
    • Hirsch, I.B.1
  • 9
    • 84960880568 scopus 로고    scopus 로고
    • Glycemic variability and diabetes complications: Does it matter? Simply put, there are better glycemic markers
    • Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! Diabetes Care 2015;38:1615-1621
    • (2015) Diabetes Care , vol.38 , pp. 1615-1621
    • Bergenstal, R.M.1
  • 10
    • 84962430629 scopus 로고    scopus 로고
    • Design of FLAT-SUGAR randomized trial of prandial insulin versus prandial GLP-1 receptor agonist together with basal insulin and metformin for high-risk type 2 diabetes
    • FLATSUGAR Trial Investigators
    • Probstfield JL, Hirsch I, O'Brien K, et al.; FLATSUGAR Trial Investigators. Design of FLAT-SUGAR randomized trial of prandial insulin versus prandial GLP-1 receptor agonist together with basal insulin and metformin for high-risk type 2 diabetes. Diabetes Care 2015;38:1558-1566
    • (2015) Diabetes Care , vol.38 , pp. 1558-1566
    • Probstfield, J.L.1    Hirsch, I.2    O'Brien, K.3
  • 11
    • 84960521846 scopus 로고    scopus 로고
    • Glycemic targets. Sec. 5. in Standards of Medical Care in Diabetes-2016
    • American Diabetes Association.
    • American Diabetes Association. Glycemic targets. Sec. 5. In Standards of Medical Care in Diabetes-2016. Diabetes Care 2016;39(Suppl. 1): S39-S46
    • (2016) Diabetes Care , vol.39 , pp. S39-S46
  • 12
    • 84955307981 scopus 로고    scopus 로고
    • Nearnormal HbA1c with stable glucosehomeostasis: The ultimate target/aim of diabetes therapy
    • Monnier L, Colette C, Dejager S, Owens DR. NearnormalHbA1c with stable glucosehomeostasis: the ultimate target/aim of diabetes therapy. Rev Endocr Metab Disord 2016;17:91-101
    • (2016) Rev Endocr Metab Disord , vol.17 , pp. 91-101
    • Monnier, L.1    Colette, C.2    Dejager, S.3    Owens, D.R.4
  • 13
    • 0032511566 scopus 로고    scopus 로고
    • Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
    • UK Prospective Diabetes Study (UKPDS) Group.
    • UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
    • (1998) Lancet , vol.352 , pp. 854-865
  • 14
    • 33846006173 scopus 로고    scopus 로고
    • The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
    • Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
    • (2006) Lancet , vol.368 , pp. 1696-1705
    • Drucker, D.J.1    Nauck, M.A.2
  • 15
    • 0031578033 scopus 로고    scopus 로고
    • Recommendations guiding physicians in biomedical research involving human subjects
    • World Medical Association Declaration of Helsinki. World Medical Association Declaration of Helsinki
    • World Medical Association Declaration of Helsinki.World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925-926
    • (1997) JAMA , vol.277 , pp. 925-926
  • 16
    • 0003975349 scopus 로고    scopus 로고
    • Directive 2001/20/EC of the European Parliament and of the council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical trials on medicinal products for human use [Internet]. Luxembourg, Accessed 15 December 2016
    • Directive 2001/20/EC of the European Parliament and of the council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical trials on medicinal products for human use [Internet], 2001. Luxembourg, Official Journal of the European Communities. Available from https://www.eortc.be/services/doc/clinical-eu-directive-04-april-01.pdf. Accessed 15 December 2016
    • (2001) Official Journal of the European Communities
  • 17
    • 0030947659 scopus 로고    scopus 로고
    • Evaluation of the Menarini-Arkray HA 8140 hemoglobin A1c analyzer
    • John WG, Braconnier F, Miedema K, Aulesa C, Piras G. Evaluation of the Menarini-Arkray HA 8140 hemoglobin A1c analyzer. Clin Chem 1997; 43:968-975
    • (1997) Clin Chem , vol.43 , pp. 968-975
    • John, W.G.1    Braconnier, F.2    Miedema, K.3    Aulesa, C.4    Piras, G.5
  • 18
    • 84876528007 scopus 로고    scopus 로고
    • Glucose variability: Where it is important and how to measure it
    • DeVries JH. Glucose variability: where it is important and how to measure it. Diabetes 2013;62:1405-1408
    • (2013) Diabetes , vol.62 , pp. 1405-1408
    • DeVries, J.H.1
  • 19
    • 79960293663 scopus 로고    scopus 로고
    • Clinical interpretation of indices of quality of glycemic control and glycemic variability
    • Rodbard D. Clinical interpretation of indices of quality of glycemic control and glycemic variability. Postgrad Med 2011;123:107-118
    • (2011) Postgrad Med , vol.123 , pp. 107-118
    • Rodbard, D.1
  • 20
    • 84867047643 scopus 로고    scopus 로고
    • Hypo-and hyperglycemia in relation to the mean, standard deviation, coefficient of variation, and nature of the glucose distribution
    • Rodbard D. Hypo-and hyperglycemia in relation to the mean, standard deviation, coefficient of variation, and nature of the glucose distribution. Diabetes Technol Ther 2012;14: 868-876
    • (2012) Diabetes Technol Ther , vol.14 , pp. 868-876
    • Rodbard, D.1
  • 21
    • 70349314777 scopus 로고    scopus 로고
    • New and improved methods to characterize glycemic variability using continuous glucose monitoring
    • Rodbard D. New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther 2009;11:551-565
    • (2009) Diabetes Technol Ther , vol.11 , pp. 551-565
    • Rodbard, D.1
  • 22
    • 84907522824 scopus 로고    scopus 로고
    • Glucose variability indices in type 1 diabetes: Parsimonious set of indices revealed by sparse principal component analysis
    • Fabris C, Facchinetti A, Sparacino G, et al. Glucose variability indices in type 1 diabetes: parsimonious set of indices revealed by sparse principal component analysis. Diabetes Technol Ther 2014;16:644-652
    • (2014) Diabetes Technol Ther , vol.16 , pp. 644-652
    • Fabris, C.1    Facchinetti, A.2    Sparacino, G.3
  • 23
    • 84878545866 scopus 로고    scopus 로고
    • Evaluation of the mean absolute glucose change as ameasure of glycemic variability using continuous glucose monitoring data
    • Kohnert K-D, Heinke P, Fritzsche G, Vogt L, Augstein P, Salzsieder E. Evaluation of the mean absolute glucose change as ameasure of glycemic variability using continuous glucose monitoring data. Diabetes Technol Ther 2013;15:448-454
    • (2013) Diabetes Technol Ther , vol.15 , pp. 448-454
    • Kohnert, K.-D.1    Heinke, P.2    Fritzsche, G.3    Vogt, L.4    Augstein, P.5    Salzsieder, E.6
  • 24
    • 70350751568 scopus 로고    scopus 로고
    • The assessment of glycemic variability and its impact on diabetesrelated complications: An overview
    • Weber C, Schnell O. The assessment of glycemic variability and its impact on diabetesrelated complications: an overview. Diabetes Technol Ther 2009;11:623-633
    • (2009) Diabetes Technol Ther , vol.11 , pp. 623-633
    • Weber, C.1    Schnell, O.2
  • 26
    • 84962110910 scopus 로고    scopus 로고
    • Glucose variability: Timing, risk analysis, and relationship to hypoglycemia in diabetes
    • Kovatchev B, Cobelli C. Glucose variability: Timing, risk analysis, and relationship to hypoglycemia in diabetes. Diabetes Care 2016;39: 502-510
    • (2016) Diabetes Care , vol.39 , pp. 502-510
    • Kovatchev, B.1    Cobelli, C.2
  • 29
    • 84971350162 scopus 로고    scopus 로고
    • Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk
    • FLAT-SUGAR Trial Investigators.
    • FLAT-SUGAR Trial Investigators. Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk. Diabetes Care 2016;39:973-981
    • (2016) Diabetes Care , vol.39 , pp. 973-981
  • 30
    • 17644412023 scopus 로고    scopus 로고
    • Inflammation, atherosclerosis, and coronary artery disease
    • Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl JMed 2005; 352:1685-1695
    • (2005) N Engl JMed , vol.352 , pp. 1685-1695
    • Hansson, G.K.1
  • 31
    • 79960403329 scopus 로고    scopus 로고
    • The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes
    • Monnier L, Wojtusciszyn A, Colette C, Owens D. The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther 2011;13:813-818
    • (2011) Diabetes Technol Ther , vol.13 , pp. 813-818
    • Monnier, L.1    Wojtusciszyn, A.2    Colette, C.3    Owens, D.4
  • 32
    • 27644546482 scopus 로고    scopus 로고
    • Glycemic variability: It's not just about A1C anymore
    • Hirsch IB. Glycemic variability: it's not just about A1C anymore! Diabetes Technol Ther 2005;7:780-783
    • (2005) Diabetes Technol Ther , vol.7 , pp. 780-783
    • Hirsch, I.B.1
  • 33
    • 85021084239 scopus 로고    scopus 로고
    • Assessment of glucose variability by professional flash glucose monitoring across therapy groups for type 2 diabetes
    • Midyett K, Cheung D, Unger JR, et al. Assessment of glucose variability by professional flash glucose monitoring across therapy groups for type 2 diabetes. Diabetes 2016;65(Suppl. 1):A222
    • (2016) Diabetes , vol.65 , pp. A222
    • Midyett, K.1    Cheung, D.2    Unger, J.R.3
  • 34
    • 84926223581 scopus 로고    scopus 로고
    • Glycemic variability in nondiabetic morbidly obese persons: Results of an observational study and review of the literature
    • Salkind SJ, Huizenga R, Fonda SJ, Walker MS, Vigersky RA. Glycemic variability in nondiabetic morbidly obese persons: results of an observational study and review of the literature. J Diabetes Sci Technol 2014;8:1042-1047
    • (2014) J Diabetes Sci Technol , vol.8 , pp. 1042-1047
    • Salkind, S.J.1    Huizenga, R.2    Fonda, S.J.3    Walker, M.S.4    Vigersky, R.A.5
  • 35
    • 35848934997 scopus 로고    scopus 로고
    • Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes
    • Kilpatrick ES, Rigby AS, Goode K, Atkin SL. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 2007; 50:2553-2561
    • (2007) Diabetologia , vol.50 , pp. 2553-2561
    • Kilpatrick, E.S.1    Rigby, A.S.2    Goode, K.3    Atkin, S.L.4
  • 36
    • 84903156652 scopus 로고    scopus 로고
    • Glycemic goals in diabetes: Tradeoff between glycemic control and iatrogenic hypoglycemia
    • Cryer PE. Glycemic goals in diabetes: tradeoff between glycemic control and iatrogenic hypoglycemia. Diabetes 2014;63:2188-2195
    • (2014) Diabetes , vol.63 , pp. 2188-2195
    • Cryer, P.E.1
  • 37
    • 84879598042 scopus 로고    scopus 로고
    • Continuous glucose monitoring accuracy results vary between assessment at home and assessment at the clinical research center
    • AP@home consortium
    • Luijf YM, Avogaro A, Benesch C, et al.; AP@home consortium. Continuous glucose monitoring accuracy results vary between assessment at home and assessment at the clinical research center. J Diabetes Sci Technol 2012;6:1103-1106
    • (2012) J Diabetes Sci Technol , vol.6 , pp. 1103-1106
    • Luijf, Y.M.1    Avogaro, A.2    Benesch, C.3
  • 38
    • 18144388647 scopus 로고    scopus 로고
    • Defining and reporting hypoglycemia in diabetes
    • American Diabetes Association Workshop on Hypoglycemia
    • American Diabetes Association Workshop on Hypoglycemia. Defining and reporting hypoglycemia in diabetes. Diabetes Care 2005;28: 1245-1249
    • (2005) Diabetes Care , vol.28 , pp. 1245-1249
  • 39
    • 0036584971 scopus 로고    scopus 로고
    • Do sensor glucose levels accurately predict plasma glucose concentrations during hypoglycemia and hyperinsulinemia?
    • Monsod TP, Flanagan DE, Rife F, et al. Do sensor glucose levels accurately predict plasma glucose concentrations during hypoglycemia and hyperinsulinemia? Diabetes Care 2002;25:889-893
    • (2002) Diabetes Care , vol.25 , pp. 889-893
    • Monsod, T.P.1    Flanagan, D.E.2    Rife, F.3
  • 40
    • 0041666413 scopus 로고    scopus 로고
    • Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous insulin infusion using insulin analogs
    • Guerci B, Floriot M, Böhme P, et al. Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous insulin infusion using insulin analogs. Diabetes Care 2003;26:582-589
    • (2003) Diabetes Care , vol.26 , pp. 582-589
    • Guerci, B.1    Floriot, M.2    Böhme, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.